Notice NOT-AG-23-004 from the NIH Guide for Grants and Contracts

Notice NOT-NS-23-073 from the NIH Guide for Grants and Contracts

Notice NOT-AG-23-001 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-081 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-OD-23-004 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) Office of Research on Womens Health (ORWH), in collaboration with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), invite applications for an Advancing Gender Inclusive Excellence (AGIE) Coordinating Center (U24 Clinical Trial Not Allowed). The purpose of the AGIE Coordinating Center will be to provide the organizational framework for the management, direction, and overall coordination of all common activities aimed at investigating strategies, approaches, and interventions enabling, and barriers preventing, women to attain leadership positions in many areas of science, technology, and engineering.

Funding Opportunity PAR-23-035 from the NIH Guide for Grants and Contracts. As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First Program), the NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First Program-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer or structural birth defect cohorts to elucidate the genetic contribution (somatic and/or germline) to childhood cancers, to investigate the genetic etiology of structural birth defects, to study the molecular basis of the associations between birth defects and increased cancer risk, or to expand the range of pediatric disorders included within the Kids First Data Resource. The program will accept applications that propose whole genome, exome, and transcriptome sequencing, as well as epigenomic assays of tumor or affected tissue, when justified. Applicants are encouraged to propose cohorts of underrepresented racial and ethnic groups or to increase racial and ethnic representation of existing Kids First Program projects. These data, and associated clinical and phenotypic data, will become part of the Kids First Data Resource Center for sharing with the research community.

Notice NOT-MD-23-002 from the NIH Guide for Grants and Contracts

Notice NOT-MD-23-003 from the NIH Guide for Grants and Contracts

Notice NOT-NS-23-062 from the NIH Guide for Grants and Contracts

Notice NOT-AG-23-003 from the NIH Guide for Grants and Contracts

Notice NOT-HL-23-075 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-072 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-076 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-079 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-078 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-067 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-23-077 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) is designed to support highly integrated research teams of three to six PD/PIs to address ambitious and challenging research questions that are important for the mission of NIGMS and are beyond the scope of one or two investigators. Collaborative program teams are expected to accomplish goals that require considerable synergy and managed team interactions. Project goals should not be achievable with a collection of individual efforts or projects. Teams are encouraged to consider far-reaching objectives that will produce major advances in their fields.Applications that are mainly focused on the creation, expansion, and/or maintenance of community resources, creation of new technologies or infrastructure development are not appropriate for this FOA.This FOA is being reissued to allow submission of applications that include NIH defined clinical trials. NIGMS will not accept clinical trials that are designed to test safety and efficacy of interventions (Phase I, Phase II, Phase III) for the purpose of future clinical treatment and/or regulatory approval in response to this FOA.

Notice NOT-HD-23-002 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-071 from the NIH Guide for Grants and Contracts

Notice NOT-MH-23-175 from the NIH Guide for Grants and Contracts